Best Liberum Ime Podcasts (2024)

1
Personalisation of therapy for people with type 2 diabetes and cardiovascular disease risk 11:56

7M ago11:56

11:56

Join Prof. Francesco Giorgino and Dr. Darren McGuire as they discuss personalisation of treatment for patients with both type 2 diabetes and cardiovascular disease. For more free education, go to ⁠⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitte…

1
Effective strategies for encouraging behaviour change 14:28

7M ago14:28

14:28

Join Prof. Francesco Giorgino and Dr. Shehla Shaikh as they discuss strategies to help support type 2 diabetes patients during cultural events, such as observation of Ramadan. For more free education, go to ⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us …

1
World Diabetes Day – Overcoming Cultural Obstacles to Personalise Diabetes Care 13:24

9M ago13:24

13:24

Join Prof. Francesco Giorgino and Dr. Alice Cheng for a discussion on the importance of being culturally sensitive during shared decision-making in type 2 diabetes care. For more free education, go to ⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter…

1
Congress special: Highlights from EASD 2023 14:00

9M ago14:00

14:00

Join Prof. Francesco Giorgino and Dr. Erika Bezerra Parente as they identify some takeaways from EASD 2023, including data and discussions on treatment non-adherence, SGLT2 inhibitors, and stigma For more free education, go to ⁠diabetes.knowledgeintopractice.com⁠⁠, where you can see all past episodes of the podcast as well as other free CME resourc…

1
Striving for Balance: Achieving Glycemic, Weight, and Cardiorenal Targets in T2D Care 12:06

12M ago12:06

12:06

In this epsisode Prof. Francisco Giorgino & Dr. Vanita Aroda explore how vital it is that we aim to control more than blood glucose levels when treating type 2 diabetes patients and whether we should strive for a balance by achieving weight, cardiovascular and renal targets as well. For more free education, go to diabetes.knowledgeintopractice.com⁠…

1
Highlights from ADA 2023 19:45

1y ago19:45

19:45

Join Prof. Francisco Giorgino & Dr. Richard E. Pratley as they discuss their highlights from the 83rd American Diabetes Association (ADA 2023) congress. The congress featured over 200 scientific sessions and symposia, and 1,400 posters. Among the topics discussed are trials investigating therapies to treat obesity in patients with type 2 diabetes (…

1
Clinical application of next-generation sequencing in advanced thyroid cancer 12:26

1y ago12:26

12:26

In today's episode, we welcome Dr. Sandip Patel, who is a Professor of Medical Oncology at the University of California, San Diego, to discuss the evolution of molecular profiling technology, focusing on how next-generation sequencing can help support patients with advanced thyroid cancer, but also how to integrate molecular profiling into clinical…

1
Adapting thyroid cancer guidelines to local care settings 15:43

1y ago15:43

15:43

In today's episode, we welcome Dr. Conor Steuer, which is Associate Professor at the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, USA, to discuss adaptation of thyroid cancer guidelines to local care settings. We touch on strategies for guideline implementation and how to overcome potential barrie…

1
The ESMO 2022 Clinical Practice Guidelines for use of systemic therapy in advanced thyroid care 15:58

1+ y ago15:58

15:58

Developments in precision medicine have led to a paradigm shift in the management of advanced thyroid cancer. The ESMO Guidelines Committee recently developed a new clinical practice guideline on the use of systemic therapy in this setting. This episode offers guideline insights into the applications recently approved therapies that have been appro…

1
Working together in the management of thyroid cancer: An oncologist and endocrinologist in conversation 21:56

2y ago21:56

21:56

In today’s episode, we welcome expert Oncologist Dr. Claire Arthur and expert Endocrinologist Dr. Sarimar Agosto Salgado to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicin…

1
Conference special: EASD 2022 Highlights | With Prof. Apostolos Tsapas 18:25

2y ago18:25

18:25

This year’s EASD was a hybrid event, with delegates able to join either in person in Stockholm, or online via the virtual platform. As usual, the congress featured a huge number of presented abstracts, symposia and other sessions. This year also saw the publication of the updated ADA-EASD consensus report on the management of hyperglycaemia in type…

1
Treatment decision-making in advanced thyroid cancer with oncogenic alterations 16:24

2y ago16:24

16:24

In today’s episode, we welcome Dr. Antonio Matrone, an endocrinologist at the University of Pisa, to discuss the many factors involved in treatment decision-making and strategies for the management of patients with advanced thyroid cancer where an oncogenic driver has been identified. References Matrone A et al. Differentiated thyroid cancer, from …

1
Personalizing care in thyroid cancer using molecular tumor boards 16:52

2y ago16:52

16:52

In today’s episode, we welcome Principal Researcher Dr. David Tamborero who was integral to the development of the Molecular Tumor Board Portal to discuss the benefits associated with molecular tumor boards and the way in which the portal can support the discussions that take place at tumor board meetings, as well as how these initiatives can suppo…

1
Publication special: Data from the SURPASS program | With Prof Carol Wysham 13:35

2y ago13:35

13:35

The SURPASS program of phase 3 clinical trials led to the 2022 FDA approval and positive CHMP opinion of the first GIP/GLP-1 receptor agonist, tirzepatide. Join Prof Carol Wysham for an examination of the clinical data from these trials and their potential impact on type 2 diabetes management. By completing this activity, you can qualify for 0.25 C…

1
Working together in the management of thyroid cancer: An oncologist and pathologist in conversation 20:57

2y ago20:57

20:57

In today’s episode, we welcome expert Oncologist Dr. Lori Wirth and expert Pathologist Dr. Thomas Giordano to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches. …

1
Tailoring GLP-1 RA dosing regimens | With Dr Harpreet Bajaj 14:05

2y ago14:05

14:05

Heterogeneity across available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes means that agents should be prescribed based on patient characteristics and preferences. So how can we best make that decision? Join Dr Harpreet Bajaj for a discussion of tailoring GLP-1 RA regimens to patient characteristics, including consider…

1
Focus on CKD: Latest guidelines and therapies | With Dr David Cherney 18:26

2y ago18:26

18:26

The last two years have provided updated guidelines on management of chronic kidney disease in type 2 diabetes alongside new regulatory approvals of pharmacotherapies. In this episode we speak to Dr David Cherney about the implications of these updates and advancements. By completing this activity, you can qualify for 0.25 CME credits. To claim you…

1
Focus on CVD: How much do we know now? | With Prof. Naveed Sattar 18:24

2y ago18:24

18:24

The past year has included the release of new guidelines on cardiovascular disease prevention and further data on cardioprotective agents in type 2 diabetes. In this episode we speak to Prof. Naveed Sattar about these guidelines and how best to help people with type 2 diabetes to reduce their cardiovascular risk. By completing this activity, you ca…

1
Advances in incretin therapy: dual agonists and beyond | With Prof. Filip Knop 16:51

2y ago16:51

16:51

This year saw the regulatory approval of the first dual GIP/GLP-1 dual agonist for type 2 diabetes. With several other multi-agonists in development, what does this mean for clinicians caring for people with type 2 diabetes? Join Prof. Filip Knop for an overview of these new and emerging agents. By completing this activity, you can qualify for 0.25…

1
Latest approaches to supporting weight loss in T2D | With Dr Robert Kushner 19:10

2y ago19:10

19:10

The importance of weight loss in type 2 diabetes was a major topic at the recent American Diabetes Association (ADA) 2022 Scientific Sessions. As weight management is a complex issue affected by both genetic and environmental factors, we shed light on the latest advances in obesity care for individuals with type 2 diabetes. Join us as we examine th…

1
Tissue is Never the Issue 22:24

2y ago22:24

22:24

Liquid biopsy has emerged as a novel diagnostic tool, enabling rapid, non-invasive molecular testing of thyroid cancers. This episode offers insight into some of the opportunities and challenges that are presented by liquid biopsy in this field. To answer questions on this topic, we have invited Professor Frederique Penault-Llorca to join us. She i…

1
Conference special: ADA 2022 | With Prof. Jennifer Green 17:40

2y ago17:40

17:40

The ADA 2022 was full of interesting symposia, updates on ongoing clinical trials, and a draft of an updated ADA-EASD consensus report. This year’s conference also put particular emphasis on weight management in the setting of type 2 diabetes as well as its associated cardiovascular and kidney comorbidities. Join us as we speak to Professor Jennife…

1
NASH: Current and future therapies | With Prof. Philip Newsome 14:16

2+ y ago14:16

14:16

This is a special episode brought to you in association with Hepatology Knowledge into Practice. NASH has historically had very few treatment options, with none currently indicated specifically for NASH. But a large number of ongoing clinical trials means that treatment may look different in the future. Join Professor Philip Newsome for an overview…

1
Resistance to RET - Targeted Therapy in Thyroid Cancer 19:22

2+ y ago19:22

19:22

Developments in RET-targeted therapies have led to a paradigm shift in the management of advanced thyroid cancer. However, resistance to these drugs has been observed to develop through a variety of mechanisms, so precise monitoring is required to detect and react to disease development. This episode offers insight into relevant mechanisms of resis…

1
Publication special: SUSTAIN FORTE | With Dr Juan Pablo Frías 14:57

2+ y ago14:57

14:57

GLP-1 receptor agonists including semaglutide have been shown to offer benefits for glycemic control, weight loss and cardiovascular protection in type 2 diabetes. But where a patient requires more glycemic control, would a higher dose be of help? The SUSTAIN FORTE trial was a randomized, double-blind, phase 3B trial that aimed to establish whether…

1
Latest data on SGLT2is in heart failure | With Prof. Javed Butler 19:02

2+ y ago19:02

19:02

In late 2020, we published an episode looking at the management of diabetes and heart failure when both present together. Since then, a wealth of evidence has been published on the effects of sodium glucose cotransporter type 2 (SGLT2) inhibitors in people with heart failure with or without type 2 diabetes. These findings have led to expanded indic…

1
Closeup on the ADA 2022 Standards of Medical Care | With Prof. Anne Peters 19:17

2+ y ago19:17

19:17

The 2022 Standards of Medical Care in Diabetes is published every year by the American Diabetes Association to reflect the latest available clinical evidence. The most significant updates this year include a lower age to begin screening for prediabetes and diabetes, an increased emphasis on individualization of treatment, and further recommendation…

1
NASH: Advances in non-invasive screening | With Dr Kenneth Cusi 14:04

2+ y ago14:04

14:04

This is a special episode brought to you in association with Hepatology Knowledge into Practice. NASH occurs in around 20% of individuals with NAFLD, and puts patients at high risk of poor outcomes including cardiovascular events and hepatocellular carcinoma. With people with type 2 diabetes and obesity at significantly increased risk for developin…

1
Update on Covid-19 and diabetes: What more do we know? | With Prof. Partha Kar 14:53

2+ y ago14:53

14:53

Description: A year ago, we published an episode looking at diabetes management in the context of ongoing restrictions in many parts of the world. Since then, a wealth of clinical data has continued to be published on the bidirectional relationship between diabetes and Covid-19, so today we’re taking a closer look at these data. We’re joined by Pro…

1
Thyroid cancer: testing for biomarkers 20:34

2+ y ago20:34

20:34

Rearranged during transfection (RET) and tropomyosin receptor kinase (TRK) fusions are involved in various adult and paediatric cancers, including thyroid cancers. There is a high mortality rate for some of these cancers, partly due to the lack of efficient detection, diagnosis, and prognosis. The US and European guidelines recommend genomic testin…

1
NASH: What’s behind the link with T2D and obesity? | With Prof. Giulio Marchesini 15:40

2+ y ago15:40

15:40

This is a special episode brought to you in association with Hepatology Knowledge into Practice. People with type 2 diabetes or obesity are at higher risk of developing non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH). Some estimates report a prevalence of NAFLD of 60% in people with type 2 diabetes, rising t…

1
NASH: Pathogenesis and pathophysiology | With Prof. Zobair Younossi 20:09

2+ y ago20:09

20:09

This is a special episode brought to you in association with Hepatology Knowledge into Practice. Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease, of which an advanced form is non-alcoholic steatohepatitis (NASH). But how does this condition develop, and why is it associated with poor outcomes? In this podcast episode, Profe…

1
Precision Medicine in Thyroid Cancer Clinical Practice Guidelines 17:40

2+ y ago17:40

17:40

In today’s episode, we’re going to talk about how precision medicine fits into thyroid cancer treatment guidelines. To answer our questions on this topic, we welcome the expertise of Dr. Lori Wirth. Dr. Wirth is Medical Director of the Center for Head and Neck Cancers at the Massachusetts General Hospital, and an Associate Professor in Medicine at …

1
An introduction to precision medicine in Thyroid cancer 17:48

2+ y ago17:48

17:48

Precision medicine is a promising field that’s opening doors to novel therapeutics for many patients. But how does it fit into thyroid cancer specifically? What treatments are available or in the pipeline, for which patient subgroup, and what are the potential benefits? We’ll start off our series by exploring these questions, and we’ve invited Dr E…

1
Haematology series | ASCO/EHA highlights continued… 17:25

3y ago17:25

17:25

In this episode we speak with Dr Navel Daver, Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA, to get his thoughts on the highlights of ASCO and EHA for patients with MDS and AML. Funding Statement: This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who hav…

1
Haematology series | ASCO and EHA conference special 25:59

3y ago25:59

25:59

At the ASCO and EHA conferences, there were many interesting posters and presentations in the field of haemato-oncology. To share their conference highlights, we’ve invited our ALL expert Dr Dieter Hoelzer, director of internal medicine at the University of Frankfurt in Germany, and our MDS and AML expert Dr Amer Zeidan, Associate Professor Of Inte…

1
Haematology series | What is fitness in acute myeloid leukaemia? 17:55

3+ y ago17:55

17:55

Adult guidelines for acute myeloid leukaemia recommend determining a patient’s fitness before treating with standard therapy, but what does this mean, what are the implications, and how does this work in practice for both adults and children? To answer our questions on this topic, we’ve invited the expertise of Dr Courtney DiNardo, Associate Profes…

1
Haematology series | Novel therapies for acute myeloid leukaemia 19:08

3+ y ago19:08

19:08

Despite available treatments, many patients with acute myeloid leukaemia, or AML, are in need of additional therapeutic options. Thankfully, there hundreds of clinical trials for new interventions that could rectify this, but which options can we start to consider, for which patients and when? To answer our questions on this topic, we’ve invited th…

1
Haematology series | Treating acute myeloid leukemia: the young and the old 21:48

3+ y ago21:48

21:48

Although most commonly a disease of the old, Acute Myeloid Leukaemia is also a significant burden for younger patients, but it can present in different ways and they should not be treated equal. So how should younger and older patients be classified and treated? To help answer some of our questions on this topic is Dr. Tapan Kadia, Associate Profes…

1
Haematology series | Risk stratification in MDS 24:02

3+ y ago24:02

24:02

For patients with myelodysplastic syndrome, or MDS, their therapy options vary considerably depending on their prognosis and risk of developing AML. Today we discuss risk stratification systems and their rationale, and consider their utility in clinical practice. To answer our questions on this topic, we welcome Professor Detlaf Haase, medical dire…

1
Haematology series | MDS: spotlight on NAE inhibitors 13:12

3+ y ago13:12

13:12

Last week we discussed the array of therapeutic options in the pipeline for patients with MDS. Today we shine a spotlight on NAE inhibitors, the first of which recently received FDA breakthrough designation to bring it to the clinic faster. To answer our questions about the current data and future therapeutic use for this novel class of drugs, we w…

1
Haematology series | Future approaches and anticipated treatments in myelodysplastic syndrome 20:09

3+ y ago20:09

20:09

Despite available treatments, there is still an unmet need to improve outcomes for some patients with myelodysplastic syndrome, or MDS. Thankfully, there is a wide array of therapies in development that could fill this gap, but which therapies can we start to consider as real future options for which patients? To answer our questions on this topic,…

1
Haematology series | Current best practice for treating MDS 18:04

3+ y ago18:04

18:04

Myelodysplastic syndrome, or MDS is a rare blood disorder that often develops into acute myeloid leukaemia. Guideline recommendations can support treatment decisions for these patients, but some questions remain about best practice. In today’s episode, we’ve invited Dr Platzbecker, clinical director in the Hematology and Cellular Therapy department…

1
We’ll be back! 0:38

3+ y ago0:38

0:38

We’re taking a break over the Christmas period, but we’ll be back in January with an exciting panel of experts discussing acute myeloid leukaemia, or AML. Until then, happy holidays and we'll see you in the new year!

1
Haematology series | Responding to adverse events during paediatric-inspired regimens in AYA patients 15:34

4y ago15:34

15:34

Asparaginase is an important component of effective treatment strategies for adolescent and young adult patients with acute lymphoblastic leukaemia, but its associated adverse events must be effectively managed. To discuss this, we welcome Dr Dieter Hoelzer, Director of Internal Medicine and ALL specialist at the University of Frankfurt in Germany.…

1
Haematology series | Strategies to reduce asparaginase hypersensitivity during treatment induction 17:40

4y ago17:40

17:40

Adolescent and young adult patients with acute lymphoblastic leukaemia have been shown to benefit from paediatric inspired treatment regimens, however these regimens present unique challenges when it comes to adverse-event management. Today we’ve invited Dr Patrick Brown, Director of the Paediatric Leukaemia Programme at Johns Hopkins Medicine, Bal…

1
Haematology series | Paediatric-inspired regimens in adult patients: a summary of available evidence 15:17

4y ago15:17

15:17

In our second episode on ALL we’ll be looking at adolescent and young adult (AYA) patients. Although these patients are commonly seen in the adult setting, evidence suggests that paediatric-inspired regimens may improve their outcomes. But how should these be implemented practically? Joining us this week is Dr Emily Curran, Assistant Professor in t…

1
Haematology series | Acute lymphoblastic leukaemia: Optimising outcomes in adolescent and young adult (AYA) patients 20:29

4y ago20:29

20:29

To start off our mini-series on ALL, this episode we’ll be looking at adolescent and young adult (AYA) patients. Although these patients are commonly seen in the adult setting, evidence suggests that pediatric-inspired regimens may improve their outcomes. But how should these be implemented practically? Joining us this week is Dr Adam DuVall, Assis…

1
Immunotherapy series | Trial data evaluating the use of PD-1/PD-L1 inhibitors in triple-negative breast cancer 21:16

4y ago21:16

21:16

Although breast cancer was once considered a “non-immunogenic” cancer, numerous studies demonstrate PD-L1 expression in the breast cancer micro-environment, and now several immune checkpoint inhibitors are under investigation in this patient group. To help us to interpret the results of all of these trials and to begin thinking about how this class…

1
Immunotherapy series | Consensus best practice approaches to metastatic head and neck squamous cell carcinoma (HNSCC) 18:30

4y ago18:30

18:30

Immune checkpoint inhibitors are a relatively new treatment option for patients with metastatic, unresectable head and neck squamous cell carcinoma (HNSCC), and so they have not yet been incorporated into clinical practice guidelines. For this reason, we interview Professor Frederic Peyrade, Head of Clinical Research and Professor of Oncology, Anto…

Podcasts Worth a Listen

Liberum Ime Podcasts

Podcasts Worth a Listen

Quick Reference Guide